| Autor: |
J, Mazieres, C, Cropet, L, Montané, F, Barlesi, P J, Souquet, X, Quantin, C, Dubos-Arvis, J, Otto, L, Favier, V, Avrillon, J, Cadranel, D, Moro-Sibilot, I, Monnet, V, Westeel, J, Le Treut, E, Brain, J, Trédaniel, M, Jaffro, S, Collot, G R, Ferretti, C, Tiffon, C, Mahier-Ait Oukhatar, J Y, Blay |
| Rok vydání: |
2019 |
| Předmět: |
|
| Zdroj: |
Annals of oncology : official journal of the European Society for Medical Oncology. 31(2) |
| ISSN: |
1569-8041 |
| Popis: |
BRAF mutations occurring in 1%-5% of patients with non-small-cell lung cancer (NSCLC) are therapeutic targets for these cancers but the impact of the exact mutation on clinical activity is unclear. The French National Cancer Institute (INCA) launched the AcSé vemurafenib trial to assess the efficacy and safety of vemurafenib in cancers with various BRAF mutations. We herein report the results of the NSCLC cohort.Tumour samples were screened for BRAF mutations in INCA-certified molecular genetic centres. Patients with BRAF-mutated tumours progressing after ≥1 line of treatment were proposed vemurafenib 960 mg twice daily. Between October 2014 and July 2018, 118 patients were enrolled in the NSCLC cohort. The primary outcome was the objective response rate (ORR) assessed every 8 weeks (RECIST v1.1). A sequential Bayesian approach was planned with an inefficacy bound of 10% for ORR. If no early stopping occurred, the treatment was of interest if the estimated ORR was ≥30% with a 90% probability. Secondary outcomes were tolerance, response duration, progression-free survival (PFS), and overall survival (OS).Of the 118 patients enrolled, 101 presented with a BRAFRoutine biomarker screening of NSCLC should include BRAFClinicalTrials.gov identifier: NCT02304809. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
